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Purpose: To conduct a mini-review of intracameral antibiotics usage 
as prophylaxis for post cataract surgery endophthalmitis.
Materials and Methods: We conducted a brief search of English 
literature regarding the recent developments in use of various intracam-
eral antibiotics as anaphylaxis for post cataract surgery endophthalmitis.
Results: The effect of prophylactic intracameral antibiotics in reducing 
post cataract surgery endophthalmitis is still a controversial subject. 
Randomized clinical trials (RCTs) are great sources to confirm benefits 
from prophylactic intracameral antibiotics. Several recent surveys have 
reported higher rates of endophthalmitis among cataract patients not 
receiving prophylactic intracameral antibiotics compared with those 
receiving antibiotics. 
Conclusion: Based on the latest findings it seems that more surgeons 
should set aside their doubts and use intracameral antibiotics as routine 
prophylaxis to reduce the rate of post cataract surgery endophthalmitis.
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Introduction
One of the most vision-threatening complica-
tions after cataract surgery is postoperative 
endophthalmitis; although the incidence rate 
of this complication is very low. Postoperative 
endophthalmitis can occur after several types of 
intraocular surgery with the highest prevalence 
reported after cataract surgery 1. Postoperative 
endophthalmitis after cataract surgery might 
cause permanent vision loss; which highlights 
the need for a prompt treatment for this condition. 
The growing rate of intracameral antibiotics’ 
usage as prophylaxis for postsurgical endoph-
thalmitis might lead to a notable reduction in 
incidence of this serious complication after 
cataract surgery worldwide. The European 
Society of Cataract and Refractive Surgery 
(ESCRS) reported that the use of intracameral 
antibiotics caused a 5-fold reduction in incidence 
of endophthalmitis after cataract surgery 2. Also, 
several other surveys by Lalitha et al., 3, Moshirfar 
et al., 4, and others have reported higher rates of 
endophthalmitis among patients not receiving 
prophylactic intracameral antibiotics compared 
with those receiving antibiotics. 
Postoperative endophthalmitis treatments
Due to changes in life expectancy and age struc-
ture of the population, cataract surgery has been 
reported as the main cause of  postoperative 
infections in Iran 5. Patients with postopera-
tive endophthalmitis undergo different kinds 
of treatments. In culture negative cases, the 
injection of intravitreal or intracameral antibi-
otics appears to be an effective treatment; while 
in culture positive cases, aggressive approaches 
such as vitrectomy might yield higher cure rates 6. 
Prophylactic antibiotics
Cefuroxime
Cefuroxime is a second-generation cephalosprin 
antibiotic, which is mostly applied in bacterial 
infections. Cefuroxime has been widely used 
in several studies as a robust prophylaxis agent 
to prevent postoperative endophthalmitis 
following cataract surgery. A partially 
masked randomized placebo-controlled 
multinational clinical study found Cefuroxime as 
a highly beneficial prophylaxis for postoperative 
endophthalmitis compared with perioperative 
Levofloxacin eyedrops 7. Patients with cata-
ract surgery well-tolerate the recommended 
doses of Cefuroxime. There is always a great 
concern about the risk of contamination when 
using this antibiotic; also the two-step dilution
process might lead to dilution errors in intraca-
meral injection of Cefuroxime 8. With regards 
to above mentioned limitations, a 2013 study 
by Keating et al., employed Aprokam as an 
intracameral Cefuroxime, which did not require 
any further dilution 8. Commercial FDA-approved 
intracameral Cefuroxime is unavailable in many 
countries such as USA 9. Also, due to lack of 
Cefuroxime ideal efficacy against gram-negative 
germs, an alternative antibiotic might be needed.
Vancomycin
Vancomycin is a broadly-active antibiotic 
against most gram-positive organisms, which 
has been used as the drug of choice in treatment 
of postoperative endophthalmitis for many 
years 10. Vancomycin covers methicillin-resistant 
Staphylococcus aureus (MRSA) responsible for 
postoperative endophthalmitis. Endophthalmitis 
Vitrectomy Study (EVS) examined the Van-
comycin concentrations in the vitreous after 
intravenous and intravitreal administration for 
treatment of postoperative endophthalmitis and 
concluded that the intravenous administration 
of Vancomycin could not reach the proper 
therapeutic doses after a single injection 11. 
Vancomycin correlation with hemorrhagic 
occlusive retinal vasculitis is a marked obstacle 
towards the prophylactic use of this antibiotic.
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Moxifloxacin
Moxifloxacin is a fourth generation, 
broad-spectrum fluoroquinolone, which is 
widely used to treat infections of the ocular 
surface, due to its well toleration in anterior 
segment 12. Haripryia et al. conducted a study to 
evaluate the effect of intracameral Moxifloxacin as 
prophylaxis against endophthalmitis development 
following cataract surgeries and concluded that 
routine intracameral Moxifloxacin prophylaxis 
reduced the overall endophthalmitis rate by 
3.5 folds 13. Moxifloxacin is recommended as a 
beneficial available antibiotic regimen to decrease 
post cataract surgery endophthalmitis in devel-
oping countries, which are more susceptible to 
endophthalmitis development due to cost-saving 
surgery procedures and instrumentation. 
Moxifloxacin represents several benefits over 
Cefuroxime and Vancomycin. There is no 
significant toxic effect regarding the intracameral 
injection of Moxifloxacin at a concentration of 150 
μg/mL for 24 hours 14. Also, the time dependent 
activity of Vancomycin can be substituted 
by biphasic behavior of Moxifloxacin, which
includes a primary concentration-dependent 
elimination resulting in a significant eradication 
of microorganisms 12. 
Conclusion
Based on the latest findings it seems that more 
surgeons should set aside their doubts and use 
intracameral antibiotics as routine prophylax-
is to reduce the rate of post cataract surgery
endophthalmitis.
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